Larsson O - Search Results

1

Expression and prognostic significance of iNOS in uveal melanoma.

Johansson CC, Mougiakakos D, Trocme E, All-Ericsson C, Economou MA, Larsson O, Seregard S, Kiessling R. Johansson CC, et al. Among authors: larsson o. Int J Cancer. 2010 Jun 1;126(11):2682-9. doi: 10.1002/ijc.24984. Int J Cancer. 2010. PMID: 19847812

2

Outcomes of patients with local recurrence of cutaneous malignant melanoma: a population-based study.

Cohn-Cedermark G, Månsson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Cohn-Cedermark G, et al. Among authors: larsson o. Cancer. 1997 Oct 15;80(8):1418-25. Cancer. 1997. PMID: 9338465

3

Expression of the insulin-like growth factor-1 receptor and its anti-apoptotic effect in malignant melanoma: a potential therapeutic target.

Kanter-Lewensohn L, Dricu A, Wang M, Wejde J, Kiessling R, Larsson O. Kanter-Lewensohn L, et al. Among authors: larsson o. Melanoma Res. 1998 Oct;8(5):389-97. doi: 10.1097/00008390-199810000-00002. Melanoma Res. 1998. PMID: 9835451

4

Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.

Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, Kono K, Hising C, Petersson M, Larsson O, Lan L, Appella E, Sette A, Celis E, Kiessling R. Rongcun Y, et al. Among authors: larsson o. J Immunol. 1999 Jul 15;163(2):1037-44. J Immunol. 1999. PMID: 10395702

5

Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma.

Cohn-Cedermark G, Månsson-Brahme E, Rutqvist LE, Larsson O, Singnomklao T, Ringborg U. Cohn-Cedermark G, et al. Among authors: larsson o. Acta Oncol. 1999;38(5):549-57. doi: 10.1080/028418699431122. Acta Oncol. 1999. PMID: 10427942

6

Expression of insulin-like growth factor-1 receptor in synovial sarcoma: association with an aggressive phenotype.

Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Xie Y, et al. Among authors: larsson o. Cancer Res. 1999 Aug 1;59(15):3588-91. Cancer Res. 1999. PMID: 10446966

7

Trends in mortality from malignant melanoma in Sweden, 1970-1996.

Cohn-Cedermark G, Månsson-Brahme E, Rutqvist LE, Larsson O, Johansson H, Ringborg U. Cohn-Cedermark G, et al. Among authors: larsson o. Cancer. 2000 Jul 15;89(2):348-55. doi: 10.1002/1097-0142(20000715)89:2<348::aid-cncr20>3.0.co;2-x. Cancer. 2000. PMID: 10918165

8

Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma.

Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Aalto Y, et al. Among authors: larsson o. Invest Ophthalmol Vis Sci. 2001 Feb;42(2):313-7. Invest Ophthalmol Vis Sci. 2001. PMID: 11157859

9

Association of HLA class I and class II antigen expression and mortality in uveal melanoma.

Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O. Ericsson C, et al. Among authors: larsson o. Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2153-6. Invest Ophthalmol Vis Sci. 2001. PMID: 11527924

10

Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.

All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. All-Ericsson C, et al. Among authors: larsson o. Invest Ophthalmol Vis Sci. 2002 Jan;43(1):1-8. Invest Ophthalmol Vis Sci. 2002. PMID: 11773005

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

544 results

Search Page

Filters